Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ACZ885
Novartis Pharmaceuticals
Muckle Wells Syndrome
1 trial -
AIN457
Novartis Pharmaceuticals
Non-infectious Uveitis
1 trial -
AIN457 150 mg
Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-Type Psoriasis
1 trial -
ASCIMINIB HYDROCHLORIDE, ASCIMINIB
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in chronic phase (CML-CP)
1 trial -
Aliskiren
Novartis Pharmaceuticals
Acute Decompensated Heart Failure
1 trial -
Asciminib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
1 trial -
Bion 1301/FUB523
Novartis Pharmaceuticals
IgA nephropathy
1 trial -
CAAA601A62301
Novartis Pharmaceuticals
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
1 trial -
CAAA617B12302
Novartis Pharmaceuticals
PSMA-positive metastatic castration-resistant prostate cancer
1 trial -
CAAA617C12301
Novartis Pharmaceuticals
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
1 trial -
CAAA617D12302
Novartis Pharmaceuticals
Oligometastatic prostate cancer (OMPC)
1 trial -
CABL001A2001B
Novartis Pharmaceuticals
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
1 trial -
CABL001J12301
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
CABL001J12302
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
CAIN457H1301
Novartis Pharmaceuticals
Ankylosing Spondylitis
1 trial -
CAIN457M2301E1
Novartis Pharmaceuticals
Hidradenitis suppurativa
1 trial -
CAIN457R12301
Novartis Pharmaceuticals
Giant cell arteritis (GCA)
1 trial -
CAIN457R1DE01
Novartis Pharmaceuticals
Giant Cell Arteritis
1 trial -
CANAKINUMAB, PEMETREXED
Novartis Pharmaceuticals
Non-small cell lung cancer
1 trial -
CBAF312D2301
Novartis Pharmaceuticals
Multiple Sclerosis in pediatric patients
1 trial -
CBYL719C2303
Novartis Pharmaceuticals
Hormone receptor positive, HER2-negative advanced breast cancer
1 trial -
CBYL719K12301
Novartis Pharmaceuticals
Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
1 trial -
CBYL719P12201
Novartis Pharmaceuticals
lymphatic malformations associated with PIK3CA mutation
1 trial -
CCTL019A2205B
Novartis Pharmaceuticals
All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.